Back to top
Eurolide Depot 3.75 mg Injection
Eurolide Depot 3.75 mg Injection

Eurolide Depot 3.75 mg Injection

Eurolide Depot 3.75 mg Injection Specification

  • Origin of Medicine
  • Synthetic
  • Salt Composition
  • Leuprorelin Acetate
  • Pacakaging (Quantity Per Box)
  • 1 vial per box
  • Drug Type
  • Hormonal Therapy
  • Ingredients
  • Leuprorelin 3.75 mg
  • Physical Form
  • Injection
  • Function
  • Used to treat prostate cancer endometriosis and uterine fibroids
  • Recommended For
  • Patients with hormone-dependent conditions
  • Dosage
  • 3.75 mg
  • Dosage Guidelines
  • Administered as a single intramuscular or subcutaneous injection once a month or as per doctors instructions
  • Suitable For
  • Adults
  • Quantity
  • 1 vial
  • Storage Instructions
  • Store in a cool dry place away from direct sunlight. Refrigeration required between 2°C to 8°C.
 
 

Eurolide Depot 3.75 mg Injection About



Eurolide Depot 3.75 mg Injection contains Leuprorelin 3.75 mg and is designed for patients with hormone-dependent conditions. This synthetic hormonal therapy is administered as a single intramuscular or subcutaneous injection once a month to treat prostate cancer, endometriosis, and uterine fibroids. Each box includes 1 vial of the Leuprorelin Acetate injection. It is suitable for adults and should be stored in a cool, dry place, with refrigeration required between 2C to 8C.

FAQs of Eurolide Depot 3.75 mg Injection:


Q: What is the recommended dosage for Eurolide Depot 3.75 mg Injection?

A: The recommended dosage for Eurolide Depot 3.75 mg Injection is 3.75 mg, administered as a single injection once a month or as per your doctors instructions.

Q: What is the storage requirement for this product?

A: Eurolide Depot 3.75 mg Injection should be stored in a cool dry place away from direct sunlight. Refrigeration between 2C to 8C is necessary.

Q: Who is this product suitable for?

A: This product is suitable for adults with hormone-dependent conditions.

Q: What is the function of this medication?

A: Eurolide Depot 3.75 mg Injection is used as a hormonal therapy to treat prostate cancer, endometriosis, and uterine fibroids.

Q: What is the salt composition of this medication?

A: The salt composition of Eurolide Depot 3.75 mg Injection is Leuprorelin Acetate.

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

More Products in Gynaecology Category

Newova 2.5 mg Tablet

Newova 2.5 mg Tablet

Ingredients : Contains active ingredient 2.5 mg of Newova salt composition

Suitable For : Adults

Dosage : 2.5 mg per tablet

Origin of Medicine : Synthetic

Dosage Guidelines : As prescribed by a healthcare professional usually once daily or as directed

Recommended For : Patients requiring treatment for the condition indicated by Newova 2.5 mg

Lupride 1 mg Injection

Lupride 1 mg Injection

Ingredients : Leuprolide acetate

Suitable For : Other, Adults and children under specific medical conditions

Dosage : 1 mg

Origin of Medicine : Synthetic

Dosage Guidelines : To be administered as per doctors prescription; typically delivered via intramuscular or subcutaneous injection

Recommended For : Individuals diagnosed with conditions related to hormone regulation

Eligard 7.5 mg Injection

Eligard 7.5 mg Injection

Ingredients : Leuprolide Acetate

Suitable For : Other, Adult men

Dosage : 7.5 mg

Origin of Medicine : Synthetic

Dosage Guidelines : Administered once a month under the supervision of a healthcare professional

Recommended For : Men with advanced prostate cancer

Glerelin 22.5 mg Injection

Glerelin 22.5 mg Injection

Ingredients : Leuprolide Acetate

Suitable For : Adults and children as prescribed by a medical professional., Other

Dosage : 22.5 mg

Origin of Medicine : Synthetic Medicine

Dosage Guidelines : Administered as an intramuscular injection every 3 months or as directed by a healthcare professional.

Recommended For : Patients with hormonesensitive conditions like advanced prostate cancer endometriosis or central precocious puberty.